<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00916110</url>
  </required_header>
  <id_info>
    <org_study_id>3242K1-1001</org_study_id>
    <secondary_id>B2271002</secondary_id>
    <nct_id>NCT00916110</nct_id>
  </id_info>
  <brief_title>Study Of Single Dose Of ATN-103 Administered To Healthy Japanese Male Subjects</brief_title>
  <acronym>ATN-103</acronym>
  <official_title>Ascending Single Dose Study Of The Safety, Tolerability, PK And PD Of ATN-103 Administered SC Or IV To Healthy Japanese Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ablynx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ablynx</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety and tolerability of ascending single SC and IV doses of ATN-103 in
      healthy Japanese male subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability are evaluated from the reported AEs, vital sign, laboratory test, etc.</measure>
    <time_frame>24weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antibody in blood and drug concentration in blood and urine are evaluated.</measure>
    <time_frame>24weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1.5mgSC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ATN-103</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4mgSC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ATN-103</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10mgSC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ATN-103</description>
  </arm_group>
  <arm_group>
    <arm_group_label>25mgSC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ATN-103</description>
  </arm_group>
  <arm_group>
    <arm_group_label>25mgIV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ATN-103</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50mgSC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ATN-103</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100mgSC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ATN-103</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200mgSC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ATN-103</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200mgIV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ATN-103</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATN-103</intervention_name>
    <description>1.5 mg solution, single subcutaneous injection</description>
    <arm_group_label>1.5mgSC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATN-103</intervention_name>
    <description>4 mg solution, single subcutaneous injection</description>
    <arm_group_label>4mgSC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATN-103</intervention_name>
    <description>10 mg solution, single subcutaneous injection</description>
    <arm_group_label>10mgSC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATN-103</intervention_name>
    <description>25 mg solution, single subcutaneous injection</description>
    <arm_group_label>25mgSC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATN-103</intervention_name>
    <description>25 mg solution, single intravenous injection</description>
    <arm_group_label>25mgIV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATN-103</intervention_name>
    <description>50 mg solution, single subcutaneous injection</description>
    <arm_group_label>50mgSC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATN-103</intervention_name>
    <description>100 mg solution, single subcutaneous injection</description>
    <arm_group_label>100mgSC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATN-103</intervention_name>
    <description>200 mg solution, single subcutaneous injection</description>
    <arm_group_label>200mgSC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATN-103</intervention_name>
    <description>200 mg solution, single intravenous injection</description>
    <arm_group_label>200mgIV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Japanese male subjects aged 20 to 45 with health determined by the study
             investigator.

          -  BMI in the range of 17.6 to 26.4.

          -  Nonsmoker or male who smokes fewer than 10 cigarettes per day.

        Exclusion Criteria:

          -  Any significant cardiovascular, hepatic, renal, respiratory, gastrointestinal,
             endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease.

          -  Acute disease state (eg, nausea, vomiting, infection, fever, or diarrhea) within 7
             days before study day 1.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josefin-Beate Holz, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ablynx NV</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Toshima</city>
        <state>Tokyo</state>
        <zip>171-0014</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2009</study_first_submitted>
  <study_first_submitted_qc>June 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2009</study_first_posted>
  <last_update_submitted>January 15, 2013</last_update_submitted>
  <last_update_submitted_qc>January 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>healthy subjects</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

